Added to YB: 2023-08-17
Pitch date: 2023-08-17
NVO [bullish]
Novo Nordisk A/S
-47.47%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 85.97
Price Target
N/A
Dividend
3.91%
EV/EBITDA
8.08
P/E
11.41
EV/Sales
4.30
Sector
Pharmaceuticals
Category
growth
$NVO: The Co. Worth More Than Denmark
NVO: Novo Nordisk’s Wegovy showed a 20% lower incidence of heart attack, stroke or cardiovascular death versus placebo in the 17,500-patient SELECT trial, exceeding the 15-17% expected and potentially strengthening insurer coverage and expanding use beyond weight loss. With the GLP-1 market estimated near $100B by decade-end, Novo could extend its leadership, though the results remain unreviewed and severe drug shortages constrain access.
Read full article (2 min)